Stocksigma LogoStocksigma Logo

Sai Life Sciences Delivers Strong Q2 FY27 Results with 23% Revenue Growth

Sai Life Sciences reported Q2 FY27 revenue from operations of ₹659 crore, up 23% YoY, driven by broad-based CRO and CDMO growth

Sai Life Sciences Delivers Strong Q2 FY27 Results with 23% Revenue Growth

Sai Life Sciences Ltd · Press Release · 06 Nov 2026, 5:43 am

Sai Life Sciences Delivers Strong Q2 FY27 Results with 23% Revenue Growth Sai Life Sciences reported Q2 FY27 revenue from operations of ₹659 crore, up 23% YoY, driven by broad-based CRO and CDMO growth. Q2 EBITDA rose 20% YoY to ₹187 crore with a 28% margin, while PAT grew 17% YoY to ₹98 crore. For H1 FY27, revenue reached ₹1,213 crore (+17% YoY), EBITDA rose to ₹335 crore (+19% YoY), and PAT reached ₹172 crore (+19% YoY). The company invested ₹621 crore in capex during H1 FY27 and expects a stronger second half.

Original exchange filing (PDF)

More announcements from Sai Life Sciences Ltd

All Sai Life Sciences Ltd announcements